1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D:
Global cancer statistics. CA Cancer J Clin 61: 69‑90, 2011.
2. Marmol I, Sanchez‑de‑Diego C, Pradilla Dieste A, Cerrada E and
Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and
future perspectives in colorectal cancer. Int J Mol Sci 18: 197, 2017.
3. Ng L, Poon RT and Pang R: Biomarkers for predicting future
metastasis of human gastrointestinal tumors. Cell Mol Life
Sci 70: 3631‑3656, 2013.
4. Yue B: Biology of the extracellular matrix: An overview.
J Glaucoma 23 (Suppl 1): S20‑S23, 2014.
5. Whiteside TL: The tumor microenvironment and its role in
promoting tumor growth. Oncogene 27: 5904‑5912, 2008.
6. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer‑related
inflammation. Nature 454: 436‑444, 2008.
7. De Wever O and Mareel M: Role of tissue stroma in cancer cell
invasion. J Pathol 200: 429‑447, 2003.
8. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev
Cancer 6: 392‑401, 2006.
9. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD and
Fidler IJ: Targeting the expression of platelet‑derived growth
factor receptor by reactive stroma inhibits growth and metastasis
of human colon carcinoma. Am J Pathol 169: 2054‑2065, 2006.
10. Wang X, Zhang W, Sun X, Lin Y and Chen W: Cancer‑associated
fibroblasts induce epithelial‑mesenchymal transition through
secreted cytokines in endometrial cancer cells. Oncol Lett 15:
5694‑5702, 2018.
11. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M,
Higashi Y, Tanaka S, Yasui W and Chayama K: Mesenchymal
stem cells enhance growth and metastasis of colon cancer. Int
J Cancer 127: 2323‑2333, 2010.
12. Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y,
Tanaka S, Yasui W and Chayama K: Mesenchymal stem cells
induce epithelial to mesenchymal transition in colon cancer cells
through direct cell‑to‑cell contact. Neoplasia 19: 429‑438, 2017.
13. Nieto MA: Epithelial plasticity: A common theme in embryonic
and cancer cells. Science 342: 1234850, 2013.
14. Bradshaw AD and Sage EH: SPARC, a matricellular protein that
functions in cellular differentiation and tissue response to injury.
J Clin Investig 107: 1049‑1054, 2001.
15. Schultz C, Lemke N, Ge S, Golembieski WA and Rempel SA:
Secreted protein acidic and rich in cysteine promotes glioma
invasion and delays tumor growth in vivo. Cancer Res 62:
6270‑6277, 2002.
16. Massi D, Franchi A, Borgognoni L, Reali UM and Santucci M:
Osteonectin expression correlates with clinical outcome in thin
cutaneous malignant melanomas. Hum Pathol 30: 339‑344, 1999.
17. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N,
Kanayama HO and Kagawa S: Analysis of the gene expression of
SPARC and its prognostic value for bladder cancer. J Urol 166:
2495‑2499, 2001.
ONCOLOGY REPORTS 45: 104, 2021
18. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H:
Frequent inactivation of SPARC by promoter hypermethylation
in colon cancers. Int J Cancer 121: 567‑575, 2007.
19. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D and
Tai IT: SPARC promoter hypermethylation in colorectal cancers
can be reversed by 5‑Aza‑2' deoxycytidine to increase SPARC
expression and improve therapy response. Br J Cancer 98:
1810‑1819, 2008.
20. Ministry of Education, Culture, Sports, Science and Technology,
Ministry of Health, Labour and Welfare, Ministry of Economy,
Trade and Industry; Ethics Guidelines for Human Genome/Gene
Analysis Research. https://www.lifescience.mext.go.jp/files/
pdf/40_213.pdf.
21. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM
and Fidler IJ: Influence of organ environment on the growth,
selection, and metastasis of human colon carcinoma cells in nude
mice. Cancer Res 48: 6863‑6871, 1988.
22. Santa María L, Rojas CV and Minguell JJ: Signals from damaged
but not undamaged skeletal muscle induce myogenic differentia‑
tion of rat bone‑marrow‑derived mesenchymal stem cells. Exp
Cell Res 300: 418‑426, 2004.
23. Ishii M, Koike C, Igarashi A, Yamanaka K, Pan H, Higashi Y,
Kawaguchi H, Sugiyama M, Kamata N, Iwata T, et al: Molecular
markers distinguish bone marrow mesenchymal stem cells from
fibroblasts. Biochem Biophys Res Commun 332: 297‑303, 2005.
24. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, Yoshida E,
Takagishi K and Kato Y: Retention of multilineage differentiation
potential of mesenchymal cells during proliferation in response
to FGF. Biochem Biophys Res Commun 288: 413‑419, 2001.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expres‑
sion data using real‑time quantitative PCR and the 2(‑Delta Delta
C(T)) method. Methods 25: 402‑408, 2001.
26. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M,
Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W and
Chayama K: Stroma‑directed imatinib therapy impairs the
tumor‑promoting effect of bone marrow‑derived mesenchymal
stem cells in an orthotopic transplantation model of colon cancer.
Int J Cancer 132: 813‑823, 2013.
27. Kawai S, Takagi Y, Kaneko S and Kurosawa T: Effect of three
types of mixed anesthetic agents alternate to ketamine in mice.
Exp Anim 60: 481‑487, 2011.
28. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N,
Pedley J, Campbell CM, Theile DR, Parsons PG and Coman WB:
Novel markers for poor prognosis in head and neck cancer. Int
J Cancer 113: 789‑797, 2005.
29. Han W, Cao F, Chen MB, Lu RZ, Wang HB, Yu M, Shi CT and
Ding HZ: Prognostic value of SPARC in patients with pancreatic
cancer: A systematic review and meta‑analysis. PLoS One 11:
e0145803, 2016.
30. Gu C, Wang X, Long T, Wang X, Zhong Y, Ma Y, Hu Z and
Li Z: FSTL1 interacts with VIM and promotes colorectal cancer
metastasis via activating the focal adhesion signalling pathway.
Cell Death Dis 9: 654, 2018.
31. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H,
Goodman SL, Kosmahl M and Klöppel G: Immunohistochemical
screening for beta6‑integrin subunit expression in adenocar‑
cinomas using a novel monoclonal antibody reveals strong
up‑regulation in pancreatic ductal adenocarcinomas in vivo and
in vitro. Histopathology 45: 226‑236, 2004.
32. Kim D, Langmead B and Salzberg SL: HISAT: A fast spliced
aligner with low memory requirements. Nat Methods 12:
357‑360, 2015.
33. Langmead B and Salzberg SL: Fast gapped‑read alignment with
Bowtie 2. Nat Methods 9: 357‑359, 2012.
34. Li B and Dewey CN: RSEM: Accurate transcript quantification
from RNA‑Seq data with or without a reference genome. BMC
Bioinformatics 12: 323, 2011.
35. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K,
Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M
and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next‑generation DNA sequencing data.
Genome Res 20: 1297‑1303, 2010.
15
36. Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q
and Xing Y: rMATS: Robust and flexible detection of differential
alternative splicing from replicate RNA‑Seq data. Proc Natl
Acad Sci USA 111: E5593‑E5601, 2014.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and
Mesirov JP: Gene set enrichment analysis: A knowledge‑based
approach for interpreting genome‑wide expression profiles. Proc
Natl Acad Sci USA 102: 15545‑15550, 2005.
38. Kim JY, Jeong D, Ahn TS, Kim HJ, Park DS, Park SY, Bae SB,
Lee S, Lee SS, Lee MS, et al: Expression of secreted protein acidic
and rich in cysteine in the stroma of a colorectal carcinoma is asso‑
ciated with patient prognosis. Ann Coloproctol 29: 93‑99, 2013.
39. Wang CS, Lin KH, Chen SL, Chan YF and Hsueh S: Overexpression
of SPARC gene in human gastric carcinoma and its clinic‑patho‑
logic significance. Br J Cancer 91: 1924‑1930, 2004.
40. Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T,
Büchler MW, Berger MR and Friess H: Osteonectin influences
growth and invasion of pancreatic cancer cells. Ann Surg 242:
224‑234, 2005.
41. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S,
Basset P, Chambon P and Gespach C: Neoplastic progression of
human colorectal cancer is associated with overexpression of the
stromelysin‑3 and BM‑40/SPARC genes. Int J Cancer 64: 70‑75,
1995.
42. Liang JF, Wang HK, Xiao H, Li N, Cheng CX, Zhao YZ, Ma YB,
Gao JZ, Bai RB and Zheng HX: Relationship and prognostic
significance of SPARC and VEGF protein expression in colon
cancer. J Exp Clin Cancer Res 29: 71, 2010.
43. Yan Q and Sage EH: SPARC, a matricellular glycoprotein with
important biological functions. J Histochem Cytochem 47:
1495‑1506, 1999.
44. Feng J and Tang L: SPARC in tumor pathophysiology and as a
potential therapeutic target. Curr Pharm Des 20: 6182‑6190, 2014.
45. Sharma S, Xing F, Liu Y, Wu K, Said N, Pochampally R,
Shiozawa Y, Lin HK, Balaji KC and Watabe K: Secreted protein
acidic and rich in cysteine (SPARC) mediates metastatic dormancy
of prostate cancer in bone. J Biol Chem 291: 19351‑19363, 2016.
46. Ordonez JL, Paraoan L, Hiscott P, Gray D, García‑Fiñana M,
Grierson I and Damato B: Differential expression of angio‑
regulatory matricellular proteins in posterior uveal melanoma.
Melanoma Res 15: 495‑502, 2005.
47. Takigawa H, Kitadai Y, Shinagawa K, Yuge R, Higashi Y,
Tanaka S, Yasui W and Chayama K: Multikinase inhibitor rego‑
rafenib inhibits the growth and metastasis of colon cancer with
abundant stroma. Cancer Sci 107: 601‑608, 2016
48. Boneschansker L, Nakayama H, Eisenga M, Wedel J,
Klagsbrun M, Irimia D and Briscoe DM: Netrin‑1 Augments
chemokinesis in CD4+ T cells in vitro and elicits a proinflamma‑
tory response in vivo. J Immunol 197: 1389‑1398, 2016.
49. Sun W, Feng J, Yi Q, Xu X, Chen Y and Tang L: SPARC acts as
a mediator of TGF‑β1 in promoting epithelial‑to‑mesenchymal
transition in A549 and H1299 lung cancer cells. Biofactors 44:
453‑464, 2018.
50. Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK,
Rocchi S, Mallavialle A, Galibert MD, Khammari A, et al: The
epithelial‑mesenchymal transition (EMT) regulatory factor
SLUG (SNAI2) is a downstream target of SPARC and AKT in
promoting melanoma cell invasion. PLoS One 7: e40378, 2012.
51. Chen J, Ji T, Wu D, Jiang S, Zhao J, Lin H and Cai X: Human
mesenchymal stem cells promote tumor growth via MAPK
pathway and metastasis by epithelial mesenchymal transition and
integrin alpha5 in hepatocellular carcinoma. Cell Death Dis 10:
425, 2019.
52. Chen L, Guo P, He Y, Chen Z, Chen L, Luo Y, Qi L, Liu Y, Wu Q,
Cui Y, et al: HCC‑derived exosomes elicit HCC progression
and recurrence by epithelial‑mesenchymal transition through
MAPK/ERK signalling pathway. Cell Death Dis 9: 513, 2018.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
